NVIDIA WEBINAR
Neural networks and other machine learning models have recently been applied to many biological problems, including drug discovery and biomarker development. Deep neural networks, combined with domain expertise, can design large, virtual chemical libraries of de novo drug-like compounds and efficiently screen them in silico to produce lead-like molecules in record time.
By attending this webinar, you'll learn:maincontent goes here
Content goes here
content goes here
Content goes here
Content goes here
Prof. Zhavoronkov is the founder and CEO of Insilico Medicine, a leader in the next-generation artificial intelligence for drug discovery, biomarker development, and aging research. Prior to Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI. Since 2012 he published over 130 peer-reviewed research papers and 2 books. For 6 years in a row he organizes the annual Aging Research for Drug Discovery and Artificial Intelligence for Healthcare forums at Basel Life/EMBO in Basel. Alex Zhavoronkov is an adjunct professor at the Buck Institute for Research on Aging.
Alex is an experienced engineering leader with extensive computer science and machine learning backgrounds. He is the ex-lead at the infrastructure & automation department at Mail.Ru, the largest European Internet company. Alex has co-authored several academic papers and MOOCs on programming and machine learning.
Polina Mamoshina is a senior research scientist at Insilico Medicine, Inc, Rockville-based bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development and a part of the computational biology team of Oxford University Computer Science Department. Her primary research interests include artificial intelligence, deep learning, biomarkers of ageing and disease and drug responses, healthcare data management, healthcare data economy. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of ageing and disease.
Add Presenter 4's Name (John Smith)
Add Presenter 4's Title (ex: CMO, ABC Company)
Content here
Webinar: Description here
Date & Time: Wednesday, April 22, 2018